Thyroid diseases, dyslipidemia and cardiovascular pathology;Doenças da tireóide, dislipidemia e patologia cardiovascular

Revista Portuguesa de Cardiologia

Volumn 27, Issue 10, 2008, Pages 1211-1236

  Neves, Celestino ^a,b   Alves, Marta ^a   Medina, José Luís ^a   Delgado, José Luís ^a  

^a UNIVERSITY OF PORTO   (Portugal)

^b HOSPITAL DE SÃO JOÃO   (Portugal)

Author keywords

Atherosclerosis; Cardiovascular disease; Lipid metabolism; Subclinical hypothyroidism; Thyroid dysfunction; Thyroid hormones

Indexed keywords

LIPOPROTEIN; THYROID HORMONE;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPERTENSION; HYPOTHYROIDISM; ISCHEMIC HEART DISEASE; LIPID METABOLISM; PREVALENCE; REVIEW;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; DYSLIPIDEMIAS; HUMANS; HYPERTHYROIDISM; HYPOTHYROIDISM; LIPOPROTEINS; PROTEIN TRANSPORT; RISK FACTORS; THYROID DISEASES; THYROID HORMONES;

EID: 58149231244     PISSN: 08702551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (184)

1. Mason RL, Hunt HM, Hurxthal L. Blood cholesterol values in hyperthyroidism and hypothyroidism. N Engl J Med 1930; 203:1273-1278.
2. Lithell H, Boberg J, Hellsing K. Serum lipoprotein and apolipoprotein concentrations and tissue lipoprotein lipase activity in overt hypothyroidism: The effect of substitution therapy. Eur J Clin Invest 1981;11:3-10.
3. Thompson GR. Plasma lipids and lipoproteins. In: Thompson GR. (ed.) A Handbook of Hyperlipidaemia. Current Science Ltd., London, pp. 23-41
4. Tall AR. Plasma cholesteryl ester transfer protein. J Lipid Res 1993;34:1255-1274.
5. Lagrost L. Regulation of cholesteryl ester transfer protein (CETP) activity: Review of in vitro and in vivo studies. Biochem Biophys Acta 1994;1215:209-236.
6. Armstrong VW, Cremer P, Eberle E, Manke A, Schulze F, Wieland H, Kreuzer H, Seidel D. The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. Atherosclerosis 1986;62:249-257.
7. Muls E, Rosseneu M, Blaton V, Lesaffre E, Lamberigts G, de Moor P. Serum lipids and apolipoproteins A-I. A-II and B in primary hypothyroidism before and during treatment. Eur J Clin Invest 1984;14:12-15.
8. Friis T, Pedersen LR. Serum lipids in hyper- and hypothyroidism before and after treatment. Clin Chim Acta 1987;162:155-163.
9. Benvenga S, Gregg R, Robbins J. Binding of thyroxine hormone to human plasma lipoprotein. J Clin Endocrinol Metab 1988;67:6-16.
10. Benvenga S, Robbins J. Enhancement of thyroxine entry into low density lipoprotein (LDL) receptor-competent fibroblasts by LDL: An additional mode of entry of thyroxine into cells. Endocrinol 1990;126: 933-941.
11. Bakker O, Hudig F, Meijssen S, Wiersinga WM. Effects of triiodothyronine and amiodarone on the promoter of the human LDL receptor gene. Biochem Biophys Res Commun 1998;240:517-521.
12. Staels B, Van Tol B, Chan B, Will H, Verhoeven G, Auwerx J. Alterations in thyroid status modulate apolipoprotein, hepatic triglyceride lipase, and low density lipoprotein receptor in rats. Endocrinol 1990;127:1144-1152.
13. Tan KCB, Shiu SWM, Kung AWC. Plasma cholesteryl ester transfer protein activity in hyper- and hypothyroidism. J Clin Endocrinol Metab 1998;83:149-153.
14. Scanu AM. Lp(a) Lipoprotein - Coping with heterogeneity. N Engl J Med 349:2089-2090, 2003
15. Duntas LH. Lipoprotein (a) and apolipoprotein (a) isoform size in thyroid disease: the quest for the Golden Fleece. Thyroid 2003;13:345-346.
16. Barnathan ES. Has lipoprotein 'little' (a) shrunk? JAMA 1993;270:2224-2225.
17. Dahlen GH. Lp(a) lipoprotein in cardiovascular disease. Atherosclerosis 1994;108:111-126.
18. Bairaktari ET, Tselepis AD, Millionis HJ, Elisaf MS. Lipoprotein (a) levels, apolipoprotein (a) phenotypes and thyroid autoimmunity. Eur J Endocrinol 1999;140:474-476.
19. Wang C, Crapo LM. The epidemiology of thyroid disease and implications for screening. Endocrinol Metab Clin North Am 1997;26:189-218.
20. Tunbridge WM, Evered DC, Hall R, Appleton D, Brewis M, Clark F, Evans JG, Young E, Bird T, Smith PA. The spectrum of thyroid disease in a community: the Whickham survey. Clin Endocrinol (Oxf) 1977;7:481-493.
21. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch Intern Med 2000;160:526-534.
22. Eggertsen R, Petersen K, Lundberg PA, Nystrom E, Lindstedt G. Screening for thyroid disease in a primary care unit with a thyroid stimulating hormone assay with a low detection limit. BMJ 1988;297:1586-1592.
23. Cooper DS. Subclinical thyroid disease: a clinician's perspective. Ann Intern Med 1998;129:135-138.
24. Franklyn J. Thyroid disease and its treatment: short- and long-term consequences. J R Coll Physicians Lond 1999;33:564-567.
25. Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med 2001;344:501-509.
26. Li Y, Chen H, Tan J, Wang X, Liang H, Sun X. Impaired release of tissue plasminogen activator from the endothelium in Graves' disease - indicator of endothelial dysfunction and reduced fibrinolytic capacity. Eur J Clin Invest 1998;28:1050-1054.
27. Sundaram V, Hanna AN, Koneru L, Newman HAI, Falko JM. Both hypothyroidism and hyperthyroidism enhance low density lipoprotein oxidation. J Clin Endocrinol Metab 1997;82:3421-3424.
28. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993;329.
29. Yallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992;339:572-575.
30. Amur SG, Shanker G, Pieringer RA. Regulation of myelin basic protein (arginine) methyltransferase by thyroid hormone in myelinogenir cultures of cells dissociated from embryonic mouse brain. J Neurochem 1984;43:494-498.
31. Ojamaa K, Klemperer JD, Klein I. Acute effects of thyroid hormone on vascular smooth muscle. Thyroid 1996;6:505-512.
32. Klein I. Thyroid hormone and the cardiovascular system. Am J Med 1990;88:631-637.
33. Vallance P, Collier J, Moncada S. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet 1989;2:997-1000.
34. Rabelo FA, Russo EM, Salgado MC, Coelho EB. Nonendothelial NO blunts sympathetic response of normotensive rats but not of SHR. Hypertension 2001;38:565-568.
35. Hermenegildo C, Medina P, Peiró M, Segarra G, Vil JM, Ortega J, Lluch S. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in hyperthyroid patients. J Clin Endocrinol Metab 2002;87:5636-5640.
36. Leiper JF, Vallance P. Biological significance of endogenous methylarginines that inhibit nitric oxide synthases. Cardiovasc Res 1999;43:542-548.
37. Böger RH, Bode-Böger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, Blaschke TF, Cooke JP. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction. Its role in hypercholesterolemia. Circulation 1998;98:1842-1847.
38. Moller N, Nielsen S, Nyholm B, Porksen N, Alberti KG, Weeke J. Glucose turnover, fuel oxidation and forearm substrate exchange in patients with thyrotoxicosis before and after medical treatment. Clin Endocrinol (Oxf) 1996;44:453-459.
39. Riis ALD, Gravholt CH, Djurhuus CB, Norrelund H, Jorgensen JO, Weeke J, Moller N. Elevated regional lipolysis in hyperthyroidism. J Clin Endocrinol Metab 2002;87:4747-4753.
40. Pestell R, Alford F, Ramos R, Sawyer S, Best J, Ward G. Insulin secretion, insulin sensitivity and glucose-mediated glucose disposal in thyrotoxicosis: a minimal model analysis. Clin Endocrinol (Oxf) 1990;33:481-493.
41. Duntas LH. Thyroid disease and lipids. Thyroid 2002;12:278-293.
42. Hansson P, Valdemarsson S, Nilsson-Ehle P. Experimental hyperthyroidism in man: effects on plasma lipoproteins, lipoprotein lipase and hepatic lipase. Horm Metab Res. 1983;15:449-52.
43. Lonn L, Stenlof K, Ottosson M, Lindroos AK, Nystrom E, Sjostrom L. Body weight and body composition changes after treatment of hyperthyroidism. J Clin Endocrinol Metab 1998;83:4269-4273.
44. Pijl H, de Meijer PHEM, Langius J, Coenegracht CI, van den Berk AH, Chandie Shaw PK, Boom H, Schoemaker RC, Cohen AF, Burggraaf J, Meinders AE. Food choice in hyperthyroidism: potential influence of the autonomic nervous system and brain serotonin precursor availability. J Clin Endocrinol Metab 2001;86:5848-5853.
45. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999;402:656-660.
46. Tschöp M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature 2000;407:908-913.
47. Wren AM, Seal LJ, Cohen MA, Brynes AE, Frost GS, Murphy KG, Dhillo WS, Ghatei MA, Bloom SR. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 2001;86:5992-5995.
48. Tschöp M, Weyer C, Tataranni PA, Devanarayan V, Ravussin E, Heiman ML. Circulating ghrelin levels are decreased in human obesity. Diabetes 2001;50:707-709.
49. Cummings DE, Weigle DS, Frayo RS, Breen PA, Ma MK, Dellinger EP, Purnell JQ. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 2002;346:1623-1630.
50. Otto B, Cuntz U, Fruehauf E, Wawarta R, Folwaczny C, Riepl RL, Heiman ML, Lehnert P, Fichter M, Tschop M. Weight gain decreases elevated plasma ghrelin concentrations of patients with anorexia nervosa. Eur J Endocrinol 2001;145:669-673.
51. Nagaya N, Uematsu M, Kojima M, Date Y, Nakazato M, Okumura H, Hosoda H, Shimizu W, Yamagishi M, Oya H, Koh H, Yutani C, Kangawa K. Elevated circulating level of ghrelin in cachexia associated with chronic heart failure: relationships between ghrelin and anabolic/catabolic factors. Circulation 2001;104:2034-2038.
52. Riis ALD, Hansen TK, Møller N, Weeke J, Jorgensen JO. Hyperthyroidism is associated with suppressed circulating ghrelin levels. J Clin Endocrinol Metab 2003;88:853-857.
53. Tanaka M, Naruo T, Muranaga T, Yasuhara D, Shiiya T, Nakazato M, Matsukura S, Nozoe S. Increased fasting plasma ghrelin levels in patients with bulimia nervosa. Eur J Endocrinol 2002;146:R1-R3.
54. Saad MF, Bernaba B, Hwu CM, Jinagouda S, Fahmi S, Kogosov E, Boyadjian R. Insulin regulates plasma ghrelin concentration. J Clin Endocrinol Metab 2002;87:3997-4000.
55. Cappiello V, Ronchi C, Morpurgo PS, Epaminonda P, Arosio M, Beck-Peccoz P, Spada A. Circulating ghrelin levels in basal conditions and during glucose tolerance test in acromegalic patients. Eur J Endocrinol 2002;147:189-194.
56. Norrelund H, Hansen TK, Orskov H, Hosoda H, Kojima M, Kangawa K, Weeke J, Moller N, Christiansen JS, Jorgensen JO. Ghrelin immunoreactivity in human plasma is suppressed by somatostatin. Clin Endocrinol (Oxf) 2002;57:539-546.
57. Rosenbaum M, Hirsch J, Murphy E, Leibel RL. Effects of changes in body weight on carbohydrate metabolism, catecholamine excretion, and thyroid function. Am J Clin Nutr 2000;71:1421-1432.
58. Shanoudy H, Soliman A, Moe S, Hadian D, Veldhuis JD, Iranmanesh A, Russell DC. Early manifestations of "sick euthyroid" syndrome in patients with compensated chronic heart failure. J Cardiac Failure 2001;7:146-152.
59. Vanderpump MP, Tunbridge WM, French JM, Appleton D, Bates D, Clark F, Grimley Evans J, Hasan DM, Rodgers H, Tunbridge F, et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol (Oxf) 1995;43:55-68.
60. Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, Braverman LE. Serum TSH, T4, and thyroid antibodies in the United States population (1988-1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinolo Metab 2002;87:489-499.
61. Perros P, McCrimmon RJ, Shaw G, Frier BM. Frequency of thyroid dysfunction in diabetic patients: value of annual screening. Diabet Med 1995;12:622-627.
62. Mouradian M, Abourizk N. Diabetes mellitus and thyroid disease. Diabetes Care 1983;6:512-520.
63. Radetti G, Paganini C, Gentili L, Bernasconi S, Betterle C, Borkenstein M, Cvijovic K, Kadrnka-Lovrencic M, Krzisnik C, Battelino T, et al. Frequency of Hashimoto's thyroiditis in children with type 1 diabetes mellitus. Acta Diabetol 1995;32:121-124.
64. DCCT Research Group: Diabetes Control and Complications Trial (DCCT): update. Diabetes 1990;13:427-433.
65. Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group: Epidemiology of Diabetes Interventions and Complications (EDIC): design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care 1999;22: 99-111.
66. Sgarbi JA, Villaça FG, Garbeline B, Villar HE, Romaldini JH. The effects of early antithyroid therapy for endogenous subclinical hyperthyroidism in clinical and heart abnormalities. J Clin Endocrinol Metab 2003;88:1672-1677.
67. Mercuro G, Panzuto MG, Bina A, Leo M, Cabula R, Petrini L, Pigliaru F, Mariotti S. Cardiac function, physical exercise capacity, and quality of life during long-term thyrotropin-suppressive therapy with levothyroxine: effect of individual dose tailoring. J Clin Endocrinol Metab 2000;85:159-164.
68. Smallridge RC. Disclosing subclinical thyroid disease. An approach to mild laboratory abnormalities and vague or absent symptoms. Postgrad Med 2000;107:143-152.
69. Sawin CT, Geller A, Wolf PA, Belanger AJ, Baker E, Bacharach P, Wilson PW, Benjamin EJ, D'Agostinho RB. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 1994;331:1249-1252.
70. Parle JV, Maisonneuve P, Sheppard MC, Boyle P, Franklyn JA. Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. Lancet 2001;358:861-865.
71. Sawin CT, Castelli WP, Hershman JM, McNamara P, Bacharach P. The aging thyroid: Thyroid deficiency in the Framingham study. Arch Intern Med 1985;145:1386-1388.
72. Riley WJ, Maclaren NK, Lezotte DC, Spillar RP, Rosenbloom AL. Thyroid autoimmunity in insulin-dependent diabetes mellitus: the case for routine screening. J Pediatr 1981;99:350-354.
73. Umpierrez GE, Latif KA, Murphy MB, Lambeth HC, Stentz F, Bush A, Kitabchi AE. Thyroid dysfunction in patients with type 1 diabetes. A longitudinal study. Diabetes Care 2003;26:1181-1185.
74. Bastenie PA, Vanhaelst L, Neve P. Coronary-artery disease in hypothyroidism. Lancet 1967;2:1221-1222.
75. Fowler PS, Swale J. Premyxoedema and coronary-artery disease. Lancet 1967;1:1077-1079.
76. Tunbridge WMG, Evered DC, Hall R Appleton D, Brewis M, Clark F, Evans JG, Young E, Bird T, Smith PA. Lipid profiles and cardiovascular disease in the Whickham areas with particular reference to thyroid failure. Clin Endocrinol 1977;7:495-508.
77. Pucci E, Chiovato L, Pinchera A. Thyroid and lipid metabolism. Int J Obesity 24(Suppl 2) 2000;S109-S112.
78. Franklyn JA, Daykin J, Betteridge J, Hughes EA, Holder R, Jones SR, Sheppard MC. Thyroxine replacement therapy and circulating lipid concentrations. Clin Endocrinol 1993;38:453-459.
79. Bauer DC, Ettinger B, Browner WS. Thyroid function and serum lipids in older women: A population-based study. Am J Med 1998;104:546-551.
80. O'Brien T, Dinneen SF, O'Brien PC, Palumbo PJ. Hyperlipidemia in patients with primary and secondary hypothyroidism. Mayo Clin Proc 1993;68: 860-866.
81. Pallas D, Koutras DA, Adamopoulos P, Marafelia P, Souvatzoglou A, Piperingos G, Moulopoulos SD. Increased mean serum thyrotropin in apparently euthyroid hypercholesterolemic patients: Does it mean occult hypothyroidism? J Endocrinol Invest 1991;14:743-746.
82. Cooper D. Subclinical hypothyroidism. N Engl J Med 2001;345:260-265.
83. Lekakis J, Papamichael C, Alevizaki M, Piperingos G, Marafelia P, Mantzos J, Stamatelopoulos S, Koutras DA. Flow mediated, endothelium-dependent vasodilatation is impaired in subjects with hypothyroidism, borderline hypothyroidism and high normal serum thyrotropin (TSH) values. Thyroid 1997;7:411-414.
84. Vanderpump M, Tunbridge W, French J, Appleton D, Bates D, Clark F, Grimley Evans J, Rodgers H, Tunbridge F, Young ET. The development of ischemic heart disease in relation to autoimmune thyroid disease in a 20-year follow-up study of an English community (Abstract). Thyroid 1996;6:155-160.
85. Hak A, Pols H, Visser T, Drexhage HA, Hofman A, Witteman JC. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam study. Ann Intern Med 2000;132:270-278.
86. Kahaly GJ. Cardiovascular and atherogenic aspects of subclinical hypothyroidism. Thyroid 2000;10:665-679.
87. Efstathiadou Z, Bitsis S, Milionis HJ, Kukuvitis A, Bairaktari ET, Elisaf MS, Tsatsoulis A. Lipid profile in subclinical hypothyroidism: Is L-thyroxine substitution beneficial? Eur J Endocrinol 2001;145:705-710.
88. Milionis HJ, Efstathiadou Z, Tselepis AD, Bairaktari ET, Tsironis LD, Tsatsoulis A, Elisaf MS. Lipoprotein (a) levels and apolipoprotein (a) isoform size in patients with subclinical hypothyroidism: Effect of treatment with L-thyroxine. Thyroid 2003;13:365-369.
89. Rader DJ, Hoeg JM, Brewer HB. Quantitation of plasma apolipoproteins in the primary and secondary prevention of coronary artery disease. Ann Intern Med 1994;120:1012-1025.
90. Hoefler G, Harnocourt F, Paschke E, Mirtle W, Pfeiffer KH, Kostner GM. Lipoprotein Lp(a): A risk factor for myocardial infarction. Arteriosclerosis 1988;8:398-401.
91. Jauhiainen M, Koskinen P, Ehnholm C, Frick MH, Manntari M, Manninen V, Huttunen JK. Lipoprotein(a) and coronary heart disease risk: A nested case-control study of the Helsinki Heart Study participants. Atherosclerosis 1991;89:59-67.
92. Ariyo AA, Thach C, Tracy R, for the Cardiovascular Health Study Investigators. Lp(a) lipoprotein, vascular disease, and mortality in the elderly. N Engl J Med 2003;349:2108-2115.
93. Miura S, Iitaka M, Yoshimura H, Kitahama S, Fukasawa N, Kawakami Y, Sakurai S, Urabe M, Sakatsume Y, Ito K, et al. Disturbed lipid metabolism in patients with subclinical hypothyroidism: Effect of L-thyroxine therapy. Intern Med 1994;33:413-417.
94. De Bruin TW, Van Barlingen H, Van Linde Sibenius Trip M, van Vuurst de Vries AR, Akveld MJ, Erkelens DW. Lipoprotein(a) and apolipoprotein B plasma concentrations in hypothyroid, euthyroid and hyperthyroid subjects. J Clin Endocrinol Metab 1993;76:121-126.
95. Caraccio N, Ferrannini E, Monzani F. Lipoprotein profile in subclinical hypothyroidism: Response to levothyroxine replacement, a randomized placebo-controlled study. J Clin Endocrinol Metab 2002;87:1533-1538.
96. Kutty KM, Bryant DG, Farid NR. Serum lipids in hypothyroidism. J Clin Enodcrinol Metab 1978;46:55-60.
97. Benvenga S, Robbins S. Lipoprotein-thyroid hormone interactions. Trends Endocrinol Metab 1996;4:194-198.
98. Soutar AK, Knight BL. Structure and regulation of the LDL receptor and its gene. Br Med Bull 1990;46:891-916.
99. Elder J, McLelland A, O'Reilley DStJ, Packard CJ, Series JJ, Sheperd J. The relationship between serum cholesterol and serum thyrotropin, thyroxine, and triiodothyronine concentrations in suspected hypothyroidism. Ann Clin Biochem 1990;27:110-113.
100. Caron P, Calazel C, Parra HJ, Hoff M, Louvet JP. Decreased HDL cholesterol in subclinical hypothyroidism: the effect of L-thyroxine therapy. Clin Endocrinol 1990;33:519-523.
101. Althaus BU, Staub JJ, Ryff-de Leche A, Oberhänslie A, Stähelin HB. LDL/HDL-changes in subclinical hypothyroidism: Possible risk factors for coronary heart disease. Clin Endocrinol 1988;28:157-163.
102. Packard CJ, Shepherd J, Lindsay GM, Gaw A, Taskinen MR. Thyroid replacement therapy and its influence on postheparin plasma lipases and apolipoprotein-B metabolism in hypothyroidism. J Clin Endocrinol Metab 1993;76:1209-1216.
103. Weintraub M, Grosskopf I, Trostanesky Y, Charach G, Rubinstein A, Stern N. Thyroxine replacement therapy enhances clearance of chylomicron remnants in patients with hypothyroidism. J Clin Endocrinol Metab 1999;84:2532-2536.
104. Illingworth DR, McClung MR, Connor WE, Alaupovic P. Familial hypercholesterolaemia and hypothyroidism: coexistence of both disorders in a young woman with severe hypercholesterolaemia. Clin Endocrinol 1981;14:145-152.
105. Wahrenberg H, Engfeld P, Arner P, Wennlund A, Ostman J. Adrenergic regulation of lipolysis in human adipocytes: Findings in hyper- and hypothyroidism. J Clin Endocrinol Metab 1986;63:631-638.
106. Feussner G, Ziegler R. Expression of type III hyperlipoproteinemia in a subject with secondary hypothyroidism bearing the apolipoprotein E 2/2 phenotype. J Intern Medicine 1991;230:183-186.
107. Müller B, Zulewski H, Huber P, Ratcliffe JG, Staub JJ. Impaired action of thyroid hormone associated with smoking in women with hypothyroidism. N Engl J Med 1995;15:964-969.
108. Bindels AJGH, Westerndorp RGJ, Froelich M, Seidell JC, Blokstra A, Smelt AHM. The prevalence of subclinical hypothyroidism at different total plasma cholesterol levels in middle aged men and women: A need for case-finding. Clin Endocrinol 1999;50:217-220.
109. Benvenga S. Effect of thyroxine on low-density lipoprotein oxidation. Another thyroid hormone nongenomic effect. J Clin Endocrinol Metab 1998;83:3377.
110. Diekman T, Demacker PN, Kastelein JJ, Stalenhoef AF, Wiersinga WM. Increased oxidizability of low-density lipoproteins in hypothyroidism. J Clin Endocrinol Metab 1998;83:1752-1755.
111. Vierhapper H, Nardi A, Grösser P, Raber W, Gess A. Low-density lipoprotein cholesterol in subclinical hypothyroidism. Thyroid 2000;10:981-984.
112. Martinez-Triguero ML, Hernandez-Mijares A, Nguyen TT, Muñoz ML, Peña H, Morillas C, Lorente D, Lluch I, Molina E. Effect of thyroid hormone replacement on lipoprotein(a), lipids, and apolipoproteins in subjects with hypothyroidism. Mayo Clin Proc 1998;73:837-84.
113. Becerra A, Bellido D, Luengo A, Piedrola G, De Luis DA. Lipoprotein(a) and other lipoproteins in hypothyroid patients before and after thyroid replacement therapy. Clin Nutr 1999;18:319-322.
114. Arem R, Escalante DA, Arem N, Morrisett JD, Patsch W. Effect of L-thyroxine therapy on lipoprotein fractions in overt and subclinical hypothyroidism, with special reference to lipoprotein(a). Metabolism 1995;44:1559-1563.
115. Pazos F, Alvarez JJ, Rubies-Prat J, Varela C, Lasuncion MA. Long-term thyroid replacement therapy and levels of lipoprotein(a) and other lipoproteins. J Clin Endocrinol Metab 1995;80:562-566.
116. Johnson JL, Duick DS. Diabetes and thyroid disease: a likely combination. Diabetes Spectrum 2002;15:140-142.
117. Saito I, Saruta T. Hypertension in thyroid disorders. Endocrinol Metab Clin North Am 1994;23: 379-386.
118. Luboshitzky R, Aviv A, Herer P, Lavie L. Risk factors for cardiovascular disease in women with subclinical hypothyroidism. Thyroid 2002;12:421-425.
119. Obuobie K, Smith J, Evans LM, John R, Davies JS, Lazarus JH. Increased central arterial stiffness in hypothyroidism. J Clin Endocrinol Metab 2002;87:4662-4666.
120. Mizuma H, Murakami M, Mori M. Thyroid hormone activation in human vascular smooth muscle cells: expression of type II iodothyronine deiodinase. Circ Res 2001;88:313-318.
121. Fommei E, Iervasi G. The role of thyroid hormone in blood pressure homeostasis: evidence from short-term hypothyroidism in humans. J Clin Endocrinol Metab 2002;87:1996-2000.
122. Gomes MC. Proteína C Reactiva: Um novo marcador "dourado" de risco cardiovascular. Rev Port Cardiol 2003;21:1329-1346.
123. Tall A. R. Protease variants, LDL, and coronary heart disease. N Engl J Med Mar 23 2006;354:1310-1312.
124. Charo IF, Ransohoff RM. Mechanisms of disease: the many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006;354:610-621.
125. Nedrebo BG, Ericsson UB, Nygard O, Refsum H, Ueland PM, Aakvaag A, Aanderud S, Lien EA. Plasma total homocysteine levels in hyperthyroid and hypothyroid patients. Metabolism 1998;47:89-93.
126. Morris MS, Bostom AG, Jacques PF, Selhub J, Rosenberg IH. Hyperhomocysteinemia and hypercholesterolemia associated with hypothyroidism in the third U.S. National Health and Nutrition Examination Survey. Atherosclerosis 2001;155:195-200.
127. Christ-Crain M, Meier C, Guglielmetti M, Huber PR, Riesen W, Staub JJ, Muller B. Elevated C-reactive protein and homocysteine values: cardiovascular risk factors in hypothyroidism? A cross-sectional and a double-blind, placebo-controlled trial. Atherosclerosis 2003;166:379-386.
128. Hussein WI, Green R, Jacobsen DW, Faiman C. Normalization of hyperhomocysteinemia with L-thyroxine in hypothyroidism. Ann Intern Med 1999;131:348-351.
129. Lien EA, Nedrebo BG, Varhaug JE, Nygard O, Aakvaag A, Ueland PM. Plasma total homocysteine levels during short-term iatrogenic hypothyroidism. J Clin Endocrinol Metab 2000;85:1049-1053.
130. Diekman MJ, van der Put NM, Blom HJ, Tijssen JG, Wiersinga WM. Determinants of changes in plasma homocysteine in hyperthyroidism and hypothyroidism. Clin Endocrinol (Oxf) 2001;54:197-204.
131. Barbe F, Klein M, Chango A, Gerard P, Quilliot D, Klein M, Lambert D, Nicolas JP, Gueant JL. Homocysteine, folate, vitamin B12, and transcobalamins in patients undergoing successive hypo- and hyperthyroid states. J Clin Endocrinol Metab 2001;86:1845-1846.
132. Deicher R, Vierhapper H. Homocysteine: a risk factor for cardiovascular disease in subclinical hypothyroidism? Thyroid 2002;12:733-736.
133. Masunaga R, Nagasaka A, Nakai A, Kotake M, Sawai Y, Oda N, Mokuno T, Shimazaki K, Hayakawa N, Kato R, Hirano E, Hagiwara M, Hidaka H. Alteration of platelet aggregation in patients with thyroid disorders. Metabolism 1997;46:1128-1131.
134. Chadarevian R, Bruckert E, Leenhardt L, Giral P, Ankri A, Turpin G. Components of the fibrinolytic system are differently altered in moderate and severe hypothyroidism. J Clin Endocrinol Metab 2001;86:732-737.
135. Hanley AJ, Williams K, Stern MP, Haffner SM. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study. Diabetes Care 2002;25:1177-1184.
136. Bakker SJ, ter Maaten JC, Popp-Snijders C, Slaets JP, Heine RJ, Gans RO. The relationship between thyrotropin and low density lipoprotein cholesterol is modified by insulin sensitivity in healthy euthyroid subjects. J Clin Endocrinol Metab 2001;86:1206-1211.
137. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 1996;221:286-289.
138. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to Clq, produced exclusively in adipocytes. J Biol Chem 1995;270:26746-26749.
139. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001;86:1930-1935.
140. Stefan N, Vozarova B, Funahashi T, Matsuzawa Y, Weyer C, Lindsay RS, Youngren JF, Havel PJ, Pratley RE, Bogardus C, Tataranni PA. Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes 2002;51:1884-1888.
141. Tomas E, Tsao TS, Saha AK, Murrey HE, Zhang Ce C, Itani SI, Lodish HF, Ruderman NB. Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc Natl Acad Sci USA 2002;99:16309-16313.
142. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, Hotta K, Nishida M, Takahashi M, Nakamura T. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999;100:2473-2476.
143. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, Nagaretani H, Matsuda M, Komuro R, Ouchi N. PPARÁ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001;50:2094-2099.
144. Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H, Hotta K, Nishida M, Takahashi M, Muraguchi M. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kB signaling through a cAMP-dependent pathway. Circulation 2000;102:1296-1301.
145. Soltys BJ, Kang D, Gupta RS. Localization of P32 protein (gClq-R) in mitochondria and at specific extramitochondrial locations in normal tissues. Histochem Cell Biol 2000;114:245-255.
146. Yoda M, Nakano Y, Tobe T, Shioda S, Choi-Miura NH, Tomita M. Characterization of mouse GBP28 and its induction by exposure to cold. Int J Obes Relat Metab Disord 2001;25:75-83.
147. Takamatsu N, Ohba K, Kondo J, Kondo N, Shiba T. Hibernation-associated gene regulation of plasma proteins with a collagen-like domain in mammalian hibernators. Mol Cell Biol 1993;13:1516-1521.
148. Vallerand AL, Lupien J, Bukowiecki LJ. Cold exposure reverses the diabetogenic effects of high-fat feeding. Diabetes 1986;35:329-334.
149. Bakker SJL, Maaten JC, Popp-Snijders C, Slaets JPJ, Heine RJ, Gans ROB. The relationship between thyrotropin and low density lipoprotein cholesterol is modified by insulin sensitivity in healthy euthyroid subjects. J Clin Endocrinol Metab 2001;86:1206-1211.
150. Soltys BJ, Kang D, Gupta RS. Localization of P32 protein (gClq-R) in mitochondria and at specific extramitochondrial locations in normal tissues. Histochem Cell Biol 2000;114:245-255.
151. Fernández-Real JM, López-Bermejo A, Casamitjana R, Ricart W. Novel interactions of adiponectin with the endocrine system and inflammatory parameters. J Clin Endocrinol Metab 2003;88:2714-2718.
152. Miura S, Iitaka M, Suzuki S, Fukasawa N, Kitahama S, Kawakami Y, Sakatsume Y, Yamanaka K, Kawasaki S, Kinoshita S, Katayama S, Shibosawa T, Ishii J. Decrease in serum levels of thyroid hormone in patients with coronary heart disease. Endocr J. 1996;43:657-663.
153. Mykkanen L, Haffner SM, Ronnemaa T, Bergman RN, Laakso M. Low insulin sensitivity is associated with clustering of cardiovascular disease risk factors. Am J Epidemiol. 1997;146:315-321.
154. Genest Jr J, Colin JS. Clustering of cardiovascular risk factors: targeting high-risk individuals. Am J Cardiol. 1995;76:8A-20A.
155. StepBakker SJL, Maaten JC, Popp-Snijders C, Slaets JPJ, Heine RJ, Gans ROB. The relationship between thyrotropin and low density lipoprotein cholesterol is modified by insulin sensitivity in healthy euthyroid subjects. J Clin Endocrinol Metab 2001;86:1206-1211.
156. Ferroni P, Basili S, Falco A, Davì G. Oxidant stress and platelet activation in hypercholesterolemia. Antioxid Redox 2004;6:747-756.
157. Becker C. Hypothyroidism and atherosclerotic heart disease: pathogenesis, medical management, and the role of coronary artery bypass surgery. Endocr Rev 1985;6:432-440.
158. Bastenie PA. Hypothyroidism and coronary heart disease. Acta Cardiol 1982;37:365-373.
159. Wiseman SA, Powell JT, Humphries SE, Press M. The magnitude of the hypercholesterolemia of hypothyroidism is associated with variation in the low density lipoprotein receptor gene. J Clin Endocrinol Metab 1993;77:108-112.
160. Klein I, Ojamaa K. Cardiovascular manifestations of endocrine disease. J Clin Endocrinol Metab 1992;75:339-342.
161. Diekman MJM, Anghelescu N, Endert E, Bakker O, Wiersinga WM. Changes in plasma low-density lipoprotein (LDL)-and high-density lipoprotein cholesterol in hypo- and hyperthyroid patients are related to changes in free thyroxine, not to polymorphisms in LDL receptor or cholesterol ester transfer protein genes. J Clin Endocrinol Metab 2000;85:1857-1862.
162. Kuusi T, Taskinen MR, Nikkila EA. Lipoproteins, lipolytic enzymes and hormonal status in hypothyroid women at different levels of substitution. J Clin Endocrinol Metab 1988;66:51-56.
163. Kinlaw WB. Atherosclerosis and the thyroid. Thyroid Today 1991;14:1-8.
164. Glueck CJ, Lang JE, Tracy T, Speirs J. The common finding of covert hypothyroidism at initial clinical evaluation for hyperlipoproteinemia. Clin Chim Acta 1991;201:113-122.
165. Lang J, Wang P, Glueck C. Myopathy associated with lipid lowering therapy in patients with previously undiagnosed or undertreated hypothyroidism. Clin Chim Acta 1996;254:85-92.
166. Paoli M, Bellabarba G, Velazquez E, Mendoza S, Molina C, Wang P, Glueck CJ. Sex steroids, lipids, and lipoprotein cholesterols in women with subclinical and overt hypothyroidism before and after L-thyroxine therapy. Clin Chim Acta 1998;275:81-91.
167. Hampl R, Kancheva R, Hill M, Biãíková M, Vondra K. Interpretation of sex hormone-binding globulin levels in thyroid disorders. Thyroid 2003;13:755-760.
168. Kung AWC, Pang RWC, Janus ED. Elevated serum lipoprotein(a) in subclinical hypothyroidism. Clin Endocrinol (Oxf) 1995;43:445-449.
169. Tzotzas T, Krassas GE, Konstantinidis T, Bougoulia M. Changes in lipoprotein(a) levels in overt and subclinical hypothyroidism before and during treatment. Thyroid 2000;10:803-808.
170. Alvarez JJ, Lasuncion MA, Olmos JM, Herrera E. Interindividual variation in the partition of lipoprotein(a) into lipoprotein subfractions. Clin Biochem 1993;26:399-408.
171. Lotz H, Salabe GB. Lipoprotein(a) increase associated with thyroid autoimmunity. Eur J Endocrinol 1997;136:87-91.
172. Klemperer JD, Ojamaa K, Klein I. Thyroid hormone therapy in cardiovascular disease. Prog Cardiovasc Dis 1996;4:329-336.
173. Chu JW, Crapo LM. The treatment of subclinical hypothyroidism is seldom necessary. J Clin Endocrinol Metab 2001;86:4591-4599.
174. McDermott MT, Ridgway EC. Subclinical hypothyroidism is mild thyroid failure and should be treated. J Clin Endocrinol Metab 2001;86:4585-4590.
175. Ross DS. Subclinical hypothyroidism. In: Braverman LE, Utiger RD. (eds.) Werner and Ingbar's The Thyroid. A Fundamental and Clinical Text. Lippincott, Williams & Wilkins, Philadelphia 2000;8,1001-1006.
176. Meier C, Staub JJ, Roth CB, Guglielmetti M, Kunz M, Miserez AR, Drewe J, Huber P, Herzog R, Muller B. TSH controlled L-thyroxine therapy reduces cholesterol levels and clinical symptoms in subclinical hypothyroidism: A double blind, placebo-controlled trial (Basel Thyroid Study). J Clin Endocrinol Metab 2001;86:4860-4866.
177. Danese MD, Ladenson PW, Meinert CL, Powe NR. Clinical review 115: effect of thyroxine therapy on serum lipoproteins in patients with mild thyroid failure: a quantitative review of the literature. J Clin Endocrinol Metab 2000; 85:2993-3001.
178. Helfand M, Redfern CC. Screening for thyroid disease: An update. Ann Intern Med 1998129:144-158.
179. Nyirenda MJ, Clark DN, Finlayson AR, Read J, Elders A, Bain M, Fox KAA, Toft AD. Thyroid disease and increased cardiovascular risk. Thyroid. 2005;15:718-724.
180. Pinchera A. Subclinical Thyroid Disease: To Treat or Not to Treat? Thyroid 2005;15:1-2.
181. Milionis HJ, Tambaki AP, Kanioglou CN, Elisaf MS, Tselepis AD, Tsatsoulis A. Thyroid substitution therapy induces high-density lipoprotein-associated platelet-activating factor-acetylhydrolase in patients with subclinical hypothyroidism: a potential antiatherogenic effect. Thyroid 2005;15:455-460.
182. Neves C, Lopes F, Medina JL. Cardiovascular disease in patients with and without hyperthyroidism. Libro de Comunicacións do XVII Congreso da Sociedade Galega de Endocrinoloxía, Nutrición e Metabolismo 2004;51.
183. Neves C, Medina JL, Carvalho D, Delgado JL. Autoimmune thyroid disease and cardiovascular risk factors. Abstracts of the Endocrine Society's 89th Annual Meeting 2007, [P3-641], 661.
184. Devdhar M, Ousman YH, Burman KD. Hypothyroidism. Endocrinol Metab Clin N Am 2007; 36: 595-615.